Adam is a trusted advisor to clients in the life sciences sector, helping them navigate their most complex transactions. He advises on a wide array of transformative matters, including M&A, licences and collaborations and financings.
As Global Head of our Life Sciences Group, Adam combines his deep understanding of the sector and strong technical expertise to enable pharmaceutical, biotech and medical device companies and investors to achieve their objectives through successful transactions.
A dual M&A and IP transactions lawyer, Adam positions clients for success in a broad range of transactions, including hybrid deals such as M&A transactions with back-end milestone payments, carve-outs, options to acquire or license and product acquisitions and divestitures. He also regularly advises clients on related transition service, manufacturing and supply, and other operational agreements.
Recognized as a leading life sciences practitioner by prestigious publications including Chambers Global and Chambers USA, Adam is valued by clients as a true problem solver. He has been shortlisted as M&A Attorney of the Year and recognized as a Life Sciences Star by LMG Life Sciences, and a Life Sciences MVP by Law360, highlighting his position as a trusted partner to those at the sector’s leading edge.
Select M&A Transactions
- CVC on its $925m carve-out acquisition of Therakos from Mallinckrodt.
- Grünenthal on its acquisition of Valinor Pharma and its product Movantik® (naloxegol).
- Merz Therapeutics on its $185m acquisition of Acorda Therapeutics through a Section 363 bankruptcy court process.
- Basilea Pharmaceutica on its acquisition from Pfizer of Fosmanogepix, a clinical-stage antifungal candidate with a novel mechanism of action to treat invasive mold infections.
- Roivant Sciences on its $7.1bn sale of Telavant to Roche.
- Novartis in its acquisition of DTx Pharma, a biotechnology company developing siRNA therapies for neuroscience indications.
- Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio® Therapeutics.
- Moderna on its acquisition of OriCiro Genomics K.K.
- Rayner Surgical on its acquisition of the product OMIDRIA® from Omeros Corporation in a transaction valued in excess of $1bn.
- Ipsen on the sale to Fusion Pharmaceuticals of rights to a radiopharmaceutical product developed for oncology indications.
- Novartis on its acquisition of Cadent Therapeutics, a clinical-stage neuroscience company.
- Engrail Therapeutics on its acquisition of NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation.
- Novartis on its acquisition of Vedere Bio, including a platform for AAV-based delivery of gene therapies and an optogenetics program.
- Altavant Sciences on its acquisition of Onspira Therapeutics, a company focused on therapeutics for rare pulmonary diseases.
- Bausch Health on its option to purchase the ophthalmology assets of Allegro Pharmaceuticals.
- Novartis on its acquisition of IFM Tre for up to $1.6bn and its option to acquire IFM Due for up to $840m.
- Celgene on its $9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.
- Novartis on its $8.7bn acquisition of AveXis, a clinical-stage gene therapy biotech company.
- Celgene on its acquisition of Impact Biomedicines for up to $7bn, a clinical stage company developing fedratinib for myelofibrosis.
- Chase Pharmaceuticals on its sale to Allergan for up to $1bn.
- Alcon Laboratories on its acquisitions of Encore Vision, RxSight and Transcend Medical.
- Bausch Health on the sale of Dendreon Pharmaceuticals to Sanpower.
Select License and Collaboration Transactions
- Novartis on its exclusive strategic license agreement with Arvinas, Inc., a clinical-stage biotechnology company, for the global development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for prostate cancer patients.
- AbbVie on its collaboration and option agreement with Parvus Therapeutics to develop and commercialize treatments for IBD, utilizing Parvus’ proprietary NavacimTM platform technology.
- Novartis on its license agreement with Legend Biotech for the exclusive worldwide rights to develop, manufacture and commercialize certain chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3.
- Novartis in its $1.3bn technology transfer agreement with Chong Kun Dang, a leading Seoul-based pharmaceutical company, for the exclusive global rights (except Korea) to develop and commercialize CKD-510, a new drug candidate developed by CKD.
- Novartis on its collaboration and license agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of a novel medicine for patients with certain cardiovascular diseases.
- SERB Pharmaceuticals in its acquisition of exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ Pharmaceuticals.
- Novartis on its global co-development and co-commercialization agreement with UCB for Parkinson’s Disease therapies.
- Spark Therapeutics on its collaboration and option agreement with Senti Biosciences with respect to the development of next-generation precision gene therapies.
- Novartis on its exclusive worldwide license and collaboration agreement with Mesoblast Limited to develop remestemcel-L for the treatment of acute respiratory distress syndrome, including that associated with COVID-19.
- Gilead Sciences on a license agreement with Xencor for the use of XmAB® antibody technologies in investigational agents for HIV.
- Gilead Sciences on its strategic collaboration with Tango Therapeutics to develop and commercialize innovative targeted immuno-oncology treatments for cancer.
- Kite, a Gilead company, on an up-to-$3bn deal to access Sangamo Therapeutics’ zinc finger nuclease technology.
- Celgene on strategic collaborations with Kyn Therapeutics, Ex Scientia, Obsidian Therapeutics, Jounce Therapeutics and Skyhawk Therapeutics.
- Gilead Sciences on its $150m collaboration with Agenus to develop and commercialize novel immuno-oncology therapies.
- Novartis on its collaboration with Cellular Biomedicine Group to support the introduction of the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.
- Novartis on strategic collaborations with Sangamo Therapeutics, Surface Therapeutics, Xencor and Homology Medicines.
